Drug Profile
Efdamrofusp alfa - Innovent Biologics
Alternative Names: IBI-302Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator AP Biosciences
- Developer Innovent Biologics
- Class Anti-inflammatories; Antineoplastics; Bispecific antibodies; Eye disorder therapies; Recombinant fusion proteins
- Mechanism of Action Angiogenesis inhibitors; Complement activation inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Wet age-related macular degeneration
- Suspended Diabetic macular oedema
- Discontinued Solid tumours
Most Recent Events
- 19 Mar 2024 Efficacy and adverse events data from a phase II trial in Wet age-related macular degeneration released by Innovent Biologics
- 06 Nov 2023 Efficacy and adverse event data from a phase II trial in Age-related macular degeneration released by Innovent Biologics
- 09 Oct 2023 Phase-III clinical trials in Age-related macular degeneration (In the elderly, In adults) in China (Intravitreous) (NCT05972473)